Rhythm Pharmaceuticals reports positive Phase 2 data for PWS treatment

June 13, 2026 8:01 AM

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) announced interim six-month results from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found